tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ALT Stock Latest News

Midday Fly By: Nike reports Q2 beat, TikTok to sell U.S. unit
The FlyMidday Fly By: Nike reports Q2 beat, TikTok to sell U.S. unit
24h ago
BB
LW
Altimmune sinks 21% to $3.98 after Phase 2b MASH data
PremiumThe Fly
Altimmune sinks 21% to $3.98 after Phase 2b MASH data
1d ago
ALT
Pemvidutide’s Strong Phase 2b Data and De-Risked Phase 3 Path in MASH Support Altimmune Buy Rating and $12 Target
PremiumRatings
Pemvidutide’s Strong Phase 2b Data and De-Risked Phase 3 Path in MASH Support Altimmune Buy Rating and $12 Target
1d ago
ALT
Balanced Risk-Reward for Altimmune’s Pemvidutide in a Crowded MASH Landscape Supports Hold Rating
PremiumRatings
Balanced Risk-Reward for Altimmune’s Pemvidutide in a Crowded MASH Landscape Supports Hold Rating
1d ago
ALT
Altimmune reports positive Phase 2b pemvidutide MASH results
PremiumCompany Announcements
Altimmune reports positive Phase 2b pemvidutide MASH results
1d ago
8K
ALT
Altimmune reports ‘positive’ results from IMPACT Phase 2b trial of pemvidutide
PremiumThe FlyAltimmune reports ‘positive’ results from IMPACT Phase 2b trial of pemvidutide
1d ago
ALT
Altimmune put volume heavy and directionally bearish
Premium
The Fly
Altimmune put volume heavy and directionally bearish
9d ago
ALT
Altimmune call volume above normal and directionally bullish
Premium
The Fly
Altimmune call volume above normal and directionally bullish
12d ago
ALT
Altimmune Announces CEO Transition Plan
PremiumCompany Announcements
Altimmune Announces CEO Transition Plan
19d ago
8K
ALT
Altimmune CEO Vipin Garg to step down, Jerry Durso to succeed
PremiumThe Fly
Altimmune CEO Vipin Garg to step down, Jerry Durso to succeed
19d ago
ALT
Altimmune announces publication of IMPACT Phase 2b trial data
PremiumThe Fly
Altimmune announces publication of IMPACT Phase 2b trial data
1M ago
ALT
Altimmune announce results from analysis of biopsies from IMPACT Phase 2b trial
PremiumThe Fly
Altimmune announce results from analysis of biopsies from IMPACT Phase 2b trial
1M ago
ALT
Altimmune price target lowered to $14 from $15 at Citizens JMP
PremiumThe FlyAltimmune price target lowered to $14 from $15 at Citizens JMP
1M ago
ALT
Altimmune Reports Q3 2025 Financial and Business Progress
Premium
Company Announcements
Altimmune Reports Q3 2025 Financial and Business Progress
1M ago
ALT
Altimmune’s Earnings Call: Financial Growth and Clinical Progress
Premium
Company Announcements
Altimmune’s Earnings Call: Financial Growth and Clinical Progress
1M ago
ALT
Altimmune’s Clinical Progress and Financial Maneuvers Justify Hold Rating Amid Transitional Phase
PremiumRatings
Altimmune’s Clinical Progress and Financial Maneuvers Justify Hold Rating Amid Transitional Phase
1M ago
ALT
Altimmune Enters New Equity Distribution Agreement
PremiumCompany Announcements
Altimmune Enters New Equity Distribution Agreement
1M ago
8K
ALT
Altimmune files $400M mixed securities shelf
PremiumThe Fly
Altimmune files $400M mixed securities shelf
1M ago
ALT
Altimmune Amends Loan Agreement with Hercules Capital
PremiumCompany Announcements
Altimmune Amends Loan Agreement with Hercules Capital
1M ago
8K
ALT
Altimmune reports Q3 EPS (21c), consensus (27c)
PremiumThe FlyAltimmune reports Q3 EPS (21c), consensus (27c)
1M ago
ALT
ALT Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
ALT Upcoming Earnings Report: What to Expect?
2M ago
ALT
Altimmune announces early completion of enrollment in RECLAIM Phase 2 trial
Premium
The Fly
Altimmune announces early completion of enrollment in RECLAIM Phase 2 trial
2M ago
ALT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >